Biomedical Research

Objective: To investigate the clinical efficacy of interventional chemoembolization combined with dendritic cell, DC-cytokine-induced killor, CIK (DC-CIK) in the treatment of colorectal cancer with liver metastasis and the influence on the survival time of patients.

Methods: Eighty cases of colorectal cancer with liver metastasis in our hospital from January 2012 to January 2014 were randomly divided into study group and control group. The study group was treated by interventional chemoembolization combined with DC-CIK treatment, and the control group was treated with conventional intravenous chemotherapy combined with DC-CIK therapy. Tumor marker, clinical efficacy, survival rate and adverse reaction of two groups were compared.

Results: After treatment, the level of tumor markers in study group was significantly lower than that in control group (P>0.05); The treatment effect of study group was better than that of control group (P>0.05); The 1 y and 2 y survival rates of study group were 75% and 45%, respectively, which were significantly better than those of control group (50% and 25%) (P>0.05); 1~5 d after treatment, part of patients showed fever, nausea and vomiting and liver pain. These patients were recovered after symptomatic treatment within two weeks. Adverse reaction of two groups was not statistically difference (P>0.05).

Conclusion: Interventional chemoembolization combined with DC-CIK in the treatment of colorectal cancer patients with liver metastasis is better with prolonged survival period of patients and tolerable adverse reaction in clinical.

Author(s): Ji-ming Du, Ai-ming Gong, Xiao-nan Dai, Fang-Wang, Wen-cai Weng
Abstract | Full-Text | PDF

Share this